Discovery stage | Validation stage | ||||||||
GEO accession number | GSE38958 | GSE33566 | GSE93606 | GSE132607 | GSE27957 | GSE28042 | |||
Reference | Huang et al34 | Yang et al35 | Molyneaux et al36 | * | †11 | †11 | |||
Country | USA | USA | UK | USA | USA | USA | |||
Disease status | IPF | Control | IPF | Control | IPF | Control | IPF | IPF | IPF |
Sample size | 70 | 45 | 93 | 30 | 57 | 20 | 74 | 45 | 75 |
Age (years, SD) | 68.2 (7.2) | 69.3 (9.3) | 67.2 (11.4) | 62.4 (14.3) | 67.4 (8.0) | 66.0 (10.6) | 66.6 (7.6) | 67.1 (8.2) | 68.9 (8.1) |
Sex (% male) | 82.6% | 60.0% | 65.6% | 46.7% | 66.7% | 60.0% | 70.3% | 88.9% | 69.3% |
Ancestry (% European) | 82.8% | 71.1% | Unknown | Unknown | Unknown | Unknown | 94.6% | 82.2% | 97.3% |
FVC % predicted (SD) | 62.4 (15.0) | Unknown | 62.0 (28.8) | Unknown | 72.2 (20.3) | Unknown | 69.7 (18.4) | 60.6 (14.3) | 65.4 (16.7) |
DLCO % predicted (SD) | 43.3 (18.7) | Unknown | 52.1 (27.9) | Unknown | 39.2 (14.1) | Unknown | 45.6 (15.4) | 43.4 (17.7) | 48.9 (18.6) |
Mortality (%) | Unknown | Unknown | Unknown | Unknown | 40.4% | Unknown | Unknown | 37.8% | 32.0% |
MUC5B genotype (% GG) | Unknown | Unknown | 28.0% | 53.8% | 40.0% | Unknown | 18.8% | Unknown | Unknown |
MUC5B genotype (% GT) | Unknown | Unknown | 66.0% | 42.3% | 50.0% | Unknown | 78.1% | Unknown | Unknown |
MUC5B genotype (% TT) | Unknown | Unknown | 6.0% | 3.8% | 10.0% | Unknown | 3.1% | Unknown | Unknown |
Immunosuppressive therapy (%) | Unknown | Unknown | 0.0% | Unknown | 0.0% | Unknown | Unknown | 4.4% | 14.7% |
*As of March 2022, the dataset with GEO accession number GSE132607 had not been associated with any published study.
†The datasets with GEO accession numbers GSE27957 and GSE28042 originated from the same study,11 where the data in GSE27957 were used in discovery and the data in GSE28042 were used as independent validation data.
DLCO, diffusing capacity of lung for carbon monoxide; GEO, Gene Expression Omnibus; MUC5B genotype, genotype for the MUC5B promoter polymorphism rs35705950.